Literature DB >> 9291938

APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1.

M C Irizarry1, M McNamara, K Fedorchak, K Hsiao, B T Hyman.   

Abstract

The recent availability of transgenic mouse models of Alzheimer disease has allowed direct in vivo assessment of the molecular and neuropathological effects of cerebral amyloid deposition. We examined 16-month-old Tg(HuAPP695. K670N-M671L)2576 mice expressing human APP K670N-M671L (APPSw), which have amyloid deposition and behavioral deficits by 11 months of age. Transgene expression is predominantly neuronal, and results in amyloid deposits, comparable to human senile plaques, at terminal zones of transgene positive neurons in cortical and limbic regions. Amyloid deposits were associated with prominent gliosis and neuritic dystrophy, without neuronal loss in CA1, loss of synaptophysin immunoreactivity in the hippocampal dentate gyrus, or loss of messenger RNA for neuronal synaptic, cytoskeletal, or metabolic proteins. We conclude that A beta is not acutely neurotoxic, but can disrupt neuronal processes and provoke an inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291938     DOI: 10.1097/00005072-199709000-00002

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  190 in total

1.  Association of microglia with amyloid plaques in brains of APP23 transgenic mice.

Authors:  M Stalder; A Phinney; A Probst; B Sommer; M Staufenbiel; M Jucker
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Alzheimer's disease in man and transgenic mice: females at higher risk.

Authors:  R S Turner
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 5.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

6.  Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models.

Authors:  Qiu-Lan Ma; Marni E Harris-White; Oliver J Ubeda; Mychica Simmons; Walter Beech; Giselle P Lim; Bruce Teter; Sally A Frautschy; Greg M Cole
Journal:  J Neurochem       Date:  2007-08-30       Impact factor: 5.372

7.  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

Authors:  Andrew W Kraft; Xiaoyan Hu; Hyejin Yoon; Ping Yan; Qingli Xiao; Yan Wang; So Chon Gil; Jennifer Brown; Ulrika Wilhelmsson; Jessica L Restivo; John R Cirrito; David M Holtzman; Jungsu Kim; Milos Pekny; Jin-Moo Lee
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

Review 8.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

9.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Authors:  Tara L Spires; Jennifer D Orne; Karen SantaCruz; Rose Pitstick; George A Carlson; Karen H Ashe; Bradley T Hyman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 10.  Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer's dementia.

Authors:  Costantino Iadecola
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.